False
May 19, 2026
Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.
3 min read
May 18, 2026
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
6 min read
May 12, 2026
The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production
6 min read
May 11, 2026
First CAR-T approach for Alzheimer’s reduces amyloid plaques in mice, while cell and gene therapies advance across blood cancers, retinal disease, amyloidosis, and FSHD
6 min read
May 5, 2026
Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody
4 min read
May 4, 2026
Intellia’s one-time HAE therapy delivers strong results as Cabaletta strikes CAR-T manufacturing deal
6 min read
April 28, 2026
FDA expands Tzield, EU clears Dupixent, and Health Canada approves denosumab antibody biosimilars
4 min read
April 21, 2026
Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma
3 min read
April 20, 2026
Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T
4 min read
April 16, 2026
The company says the acquisition will strengthen downstream antibody manufacturing and help biopharma customers scale more efficiently.
False